| __timestamp | Arrowhead Pharmaceuticals, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 34916000 |
| Thursday, January 1, 2015 | 34718089 | 36949000 |
| Friday, January 1, 2016 | 40998209 | 45240000 |
| Sunday, January 1, 2017 | 32022880 | 62416000 |
| Monday, January 1, 2018 | 19110051 | 81289000 |
| Tuesday, January 1, 2019 | 26556257 | 100359000 |
| Wednesday, January 1, 2020 | 52275890 | 105326000 |
| Friday, January 1, 2021 | 80981000 | 122356000 |
| Saturday, January 1, 2022 | 124431000 | 152848000 |
| Sunday, January 1, 2023 | 90932000 | 184259000 |
| Monday, January 1, 2024 | 98761000 |
Unleashing the power of data
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and Arrowhead Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Corcept's SG&A expenses have shown a remarkable upward trend, peaking in 2023 with a 428% increase from 2014. In contrast, Arrowhead's expenses have also grown, but at a steadier pace, with a 304% rise over the same period. Notably, Corcept's expenses surpassed Arrowhead's consistently from 2017 onwards, highlighting a more aggressive investment in administrative and sales functions. However, data for 2024 is incomplete, leaving room for speculation on future trends. This financial insight provides a window into the strategic priorities of these biotech giants, reflecting their commitment to growth and market expansion.
Cost Management Insights: SG&A Expenses for Eli Lilly and Company and Corcept Therapeutics Incorporated
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Biogen Inc. and Corcept Therapeutics Incorporated
BeiGene, Ltd. or Corcept Therapeutics Incorporated: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Arrowhead Pharmaceuticals, Inc.
Genmab A/S and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Viatris Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Arrowhead Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and MannKind Corporation